Lixisenatide significantly increases the probability of a A1C response in patients not adequately controlled on oral antihyperglycemic agents

GAGLIARDINO JJ ET AL.

Montreal

Congreso; 16th Annual Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism?s (CDA/CSEM) annual conference; 2013

Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism

Aims: To evaluate the response to lixisenatide, a novel once-daily glucagon-like peptide-1 receptor agonist, as add on to 1 oral antihyperglycemic agent (OAA) and 2 OAAs in patients with type 2 diabetes mellitus (T2DM) and the patient characteristics that may predict a response. Methods: Data were extracted from 5 randomized, 24-week, double-blind, placebo-controlled trials of the efficacy and safety of lixisenatide in patients with T2DM with inadequate glycemic control: GetGoal-M, -F1, -S, -P and -M Asia. Response was defined as the proportion of patients achieving A1C